CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc.

1:10-cv-00342

Overview

Case Number 1:10-cv-00342
Filing Date 2010-04-26
Status Terminated
Termination Date 2010-12-15
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Movant

AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)

Represented By

10 Attorneys Listed

Kenneth M. Frankel

Email: kenneth.frankel@finnegan.com

Mary K. Ferguson

Email: Mary.Ferguson@finnegan.com

William E. McShane

Email: wmcshane@cblh.com

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Ford F. Farabow

Email: ford.farabow@finnegan.com

Charles E. Lipsey

Email: charles.lipsey@finnegan.com

Dana Kathryn Severance

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

York M. Faulkner

Email: york.faulkner@finnegan.com

Nathaniel S. Edwards

Email: nathaniel.edwards@finnegan.com

Bruce S. Manheim , Jr.

Email: bruce.manheim@ropesgray.com

Defendant

AstraZeneca AB NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Dana Kathryn Severance

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Mylan Pharmaceuticals Inc. Operating Company

Represented By

6 Attorneys Listed

Megan C. Haney

Phillips, Goldman & Spence, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman & Spence, P.A., 1200 North Broom Street

John C. Phillips , Jr.

Phillips, Goldman & Spence, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman & Spence, P.A., 1200 North Broom Street

Eric R. Hunt

Email: ehunt@rmmslegal.com

William A. Rakoczy

Email: wrakoczy@rmmslegal.com

Joseph T Jaros

Email: jjaros@rmmslegal.com

Paul J. Molino

Email: pmolino@rmmslegal.com

Plaintiff

The Brigham and Women's Hospital, Inc. Operating Company

Represented By

2 Attorneys Listed

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Dana Kathryn Severance

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

IPR Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Mary W. Bourke

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4320

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Dana Kathryn Severance

Womble Carlyle Sandridge Rice

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

Womble Carlyle Sandridge Rice, 222 Delaware Avenue

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 9 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2013-12-09
2:13-cv-03438

MUSC Foundation for Research Development v. AstraZeneca Pharmaceuticals LP

Asserted Patent
Status: SCD
U.S. District Court 2013-07-31
2:13-cv-02078

MUSC Foundation for Research Development v. AstraZeneca Pharmaceuticals LP

Asserted Patent
Status: SCD
U.S. District Court 2011-04-05
2:11-cv-00807

Palmetto Pharmaceuticals LLC v. AstraZeneca Pharmaceuticals LP

Asserted Patent
Status: SCD
U.S. District Court 2010-10-26
1:10-cv-00915

AstraZeneca UK Limited v. Watson Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00344

AstraZeneca Pharmaceuticals LP v. Sandoz Inc.

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00345

AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd.

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00339

AstraZeneca Pharmaceuticals LP v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00341

AstraZeneca Pharmaceuticals LP v. Glenmark Generics Inc. USA

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00346

AstraZeneca Pharmaceuticals LP v. Teva Pharamceuticals USA, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6858618
Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Filed: 2001-11-16
Issued: 2005-02-22
Expired (Term Ended) +31d PTA
Expires: 2021-12-17
US7030152
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Filed: 1999-08-31
Issued: 2006-04-18
Expired (Term Ended)
Expires: 2019-08-31

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

26

Dispositive

23

Granted

2

Denied

0

Pending / Review

19

Motions by Category

Procedural / Extension Motion 3 Motion to Dismiss 23

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
OPINION regarding Motion to Dismiss. Signed by Judge Robert B. Kugler on 12/15/2010. (dlk) (Entered: 12/15/2010)
Entry #38 • 2010-12-15 Document →
Motion to Dismiss Granted
ORDER granting (13) Motion to Dismiss for Lack of Subject Jurisdiction (CASE CLOSED) in case 1:10-cv-00345-RBK-KW; granting (14) Motion to Dismiss for Lack of S...
Entry #39 • 2010-12-15 Document →
Motion to Dismiss Pending / Under Review
REQUEST for Oral Argument by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc., The Brigham and Women's Hospital, Inc. re 14 MOTION to Di...
Entry #36 • 2010-11-12 Document →
Motion to Dismiss Pending / Under Review
REQUEST for Oral Argument by Mylan Pharmaceuticals Inc. re 14 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter. (Phillips, John) (Entered: 11/...
Entry #37 • 2010-11-12 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of 34 Reply Brief in Support of Its Rule 12(b)(1) and 12(b)(6) Motion to Dismiss the Amended Complaint by Mylan Pharmaceuticals Inc.. (Phillips...
Entry #35 • 2010-11-09 Document →
Motion to Dismiss Pending / Under Review
SEALED REPLY BRIEF re 14 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Mylan Pharmaceuticals Inc.. (Phillips, John) (Entered: 11/0...
Entry #34 • 2010-11-08 Document →

Docket Entries

(54 total)
Pleading / Complaint

COMPLAINT filed against Mylan Pharmaceuticals Inc. - ( Filing fee $ 350, receipt number 0311725841.) - filed by AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc., AstraZeneca AB. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(els) (Entered: 04/27/2010)

Entry #1 • 2010-04-26
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (els) (Entered: 04/27/2010)

Entry #2 • 2010-04-26
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,858,618 B2; 7,030,152 B1; (els) (Entered: 04/27/2010)

Entry #3 • 2010-04-27
1

Disclosure Statement pursuant to Rule 7.1 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc.. (Bourke, Mary) (Entered: 04/28/2010)

Entry #4 • 2010-04-28
1
Pleading / Complaint

AMENDED COMPLAINT against Mylan Pharmaceuticals Inc.- filed by AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc., AstraZeneca AB, The Brigham and Women's Hospital, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Bourke, Mary) (Entered: 04/30/2010)

Entry #5 • 2010-04-30
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc